News

Much research has focused on understanding how mutations in a protein kinase termed LRRK2, predisposes to Parkinson’s disease. Most pathogenic mutations occur within the kinase domain (G2019S) and GTPase ROC/COR domain (R1441G and Y1699C) of LRRK2.

 …more
Yu-Chiang Lai, a postdoc in Miratul Muqit’s lab at the MRC PPU, has been awarded a Birmingham Fellowship to establish his lab, aiming to understand the molecular mechanism of skeletal muscle atrophy and how exercise can improve health. …more

Derailment of the PI3K signalling network contributes to many human diseases including cancer.

 …more

The University of Dundee held a special celebration for its staff members who had been in post for 25 years!

 …more

There is compelling evidence that mutations which stimulate the activity of the LRRK2 protein kinase, cause Parkinson’s disease. Orally bioavailable, brain penetrant and potent LRRK2 kinase inhibitors are in the later stages of clinical development. There is also increasing indication that LRRK2 is over-activated in some patients with sporadic Parkinson’s disease.

 …more

Mutations that activate the LRRK2 protein kinase, predispose to Parkinson’s disease, suggesting that LRRK2 inhibitors might have therapeutic benefit.

 …more
Mutations that activate the Leucine-rich repeat kinase 2 (LRRK2) protein kinase, predispose to Parkinson’s disease, suggesting that LRRK2 inhibitors might have therapeutic benefit. …more

Adrien Rousseau has opened a new laboratory in the MRC PPU to investigate signalling pathways controlling proteasome homeostasis.

 …more
Ying (Ivonna) Fan and Esther Sammler from the Alessi lab just returned from a visit to Professor Tolosa’s group in Barcelona, Spain where they collected clinical samples from LRRK2 mutation carriers, idiopathic Parkinson’s patients and controls. …more

Many congratulation to Dr Guadalupe Sabio, who was an PhD student with Ana Cuenda in the MRC PPU from 2003-2005, who has just been awarded a highly prestigious and sought after EMBO-YIP award.

 …more